Two Phase 3 trials have shown that epratuzumab did not meet its primary endpoints for treating SLE. Meanwhile, a Phase 3 study has shown adalimumab is effective for treating enthesitis-related arthritis in juveniles…
Adalimumab Remains Safe, Effective for Psoriasis
NEW YORK (Reuters Health)—In adults with chronic plaque psoriasis, adalimumab (Humira, AbbVie) was generally well tolerated and effective during five years of therapy, according to a new analysis. The interim analysis is from ESPRIT, a 10-year multinational post-marketing registry. “Clinical trials are not the real world,” in part because patients with comorbidities are screened out…
Personal Beliefs Affect Medication Adherence for RA Patients
A recent British study concluded that determining a rheumatoid arthritis patient’s personal beliefs about medication could aid rheumatologists in regularly addressing medication adherence during visits.
Biosimilar Drug Updates Reported from EULAR
At the 2015 meeting of the European League Against Rheumatism in June, multiple studies were presented comparing the use of different biosimilar and biologic drugs in treating rheumatoid arthritis…
What’s New in Inflammatory Arthritis?
Rheumatology experts at the ACR’s State-of-the-Art Clinical Symposium in Chicago discuss latest drug therapies, insights into axial spondyloarthritis and bone erosion, repair
Rheumatology Drug Updates
Information on new approvals and medication safety that rheumatologists need to know
Rheumatology Drug Updates
Information on new approvals and medication safety rheumatologists need to know
- « Previous Page
- 1
- …
- 7
- 8
- 9